Helsinn and Lyfebulb Announce Third Annual Patient-Driven Innovation Summit & Award in Oncology to be held during the 14th Monaco Biennale of Oncology 2020

NEXT STORY
Akari Therapeutics Reports Second Quarter 2019 Financial Results And Highlights Recent Clinical Progress
PREV STORY
ChemioCare Strengthens its Proposed Slate of Directors with the Nomination of Multiple Myeloma Expert Dr. Mohamad Hussein
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Roche’s Tecentriq in combination with chemotherapy (including Abraxane) meets primary endpoint of improved pathological complete response, regardless of PD-L1 status, as initial treatment for people with early triple-negative breast cancer

author_avatar
NASDAQ Market News

FIT Biotech: Conversion of FIT Biotech Oy’s Convertible Capital Notes into shares

FIT Biotech Oy Company release September 19, 2017 at 10:00 AM EET Conversion of ...

author_avatar
NASDAQ Market News

Cellectar Biosciences Announces USPTO Issues Patent for New Phospholipid Drug Conjugate (PDC) with Paclitaxel

MADISON, Wis., May 25, 2016 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (“the Company”), ...

author_avatar
NASDAQ Market News